Meihua International Medical Technologies Co. Ltd. (MHUAF) fair value: what the stock is really worth
As of Oct 15, 2026: fair value of Meihua International Medical Technologies Co. Ltd. $4.73, price $6.50, upside -27.2%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
56‑month range $2.05 – $3,900 · fair‑value band $3.95 – $6.26 · the $6.50 price screens above the $4.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Meihua International Medical Technologies Co. in your weekly email
Every Wednesday you see whether Meihua International Medical Technologies Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Meihua International Medical Technologies Co., Ltd. engages in the research and development, manufacture, and sale of medical devices in the People's Republic of China, Europe, North America, South America, Asia, Africa, and Oceania.
Show moreShow less
The company offers Class I disposable medical devices, including disposable medical X-ray films, medical dry films, dry laser imagers, gauze bandages, examination gloves, pharmaceutical packaging materials and containers, low-density polyethylene bottles for eye drops, and high-density polyethylene bottles for tablets; Class II products, such as disposable full anesthesia kits, medical brush, woman's examination kits, urethral catheterization kits, disposable bracelet, tube cleaning brush, gynecological examination and sterile surgical dressing kits, medical hand scrub, cervical sampling swab, catheter, hand washing brush, cervical liquid based cell sampler, surgical hats, suction connecting tube, nasal oxygen tube, endotracheal intubation, medical masks, anal bags, and suction connecting tube, etc.; and Class III disposable medical devices, such as disposable infusion pumps, anesthesia puncture kits, electronic pumps, etc.
It also offers disposable plastic baby bottles, NB/PSN rubber covers and 8.2mL folded spoons for tools and containers, etc.; Class II 6866 medical polymer materials and products, including transfusion equipment and pipelines, endotracheal intubation for respiratory anesthesia or ventilation; medical devices, such as medical x-ray films and multi-functional self-extracting X-ray film machines; and provides SaaS development service to develop customized SaaS system covering the entire project lifecycle, including demand analysis, design, research and development, testing, launch, and maintenance support.
The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. The company was founded in 1991 and is headquartered in Yangzhou, the People's Republic of China.
Stock analysis
Meihua International Medical Technologies Co. Ltd. (MHUAF) currently trades at $6.50, while our model-based Fair Value estimate is $4.73, 27.2% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 21 models at a data quality of 96/100, which puts the data coverage at medium.
Scenario range: $3.95 (bear) to $6.26 (bull), the price of $6.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Meihua International Medical Technologies Co. Ltd. reported revenue of $61.8M in FY2025 versus $104M in FY2021, a compound −12.2%/yr. Reported net income was $6.8M in FY2025, compounding −24.6%/yr from FY2021.
Key figures
Market cap $6.0M · P/E ratio 0.4 · P/S ratio 0.04 · EPS (TTM) $18.04 · Net margin 11.0% · Return on equity 3.9% · Return on assets (EBIT) 9.2% · Operating margin 21.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 83% below its 52-week high and 217% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −36% fair-value upside, at −27%, MHUAF screens cheaper than that median.
Fair Value models
Bear$3.95Fair Value $4.73Bull$6.26
Price $6.50 · Upside -27.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($14.28 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−36.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.1%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−25.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−25.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 13%
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Compare Meihua International Medical Technologies Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 188 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score36 · Bottom 25%
Fair Value upside−27.2% · Below median
Profitability
Return on equity (12 months)3.9% · Below median
Return on assets3.3% · Below median
Net margin (12 months)11.0% · Above median
Operating margin (12 months)21.2% · Top 25%
Growth and dividend
Revenue growth−53.8% · Bottom 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)0.4× · Cheapest 25%
P/S (12 months)0.10× · Cheapest 25%
Price / free cash flow10.8× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)0· sector 36
PAST (return on equity)16· sector 28
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Meihua International Medical Technologies Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/MHUAF
Frequently asked questions
Is Meihua International Medical Technologies Co. Ltd. (MHUAF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $4.73 versus a price of $6.50, about −27% upside (overvalued).
What is the fair value of MHUAF?
Our model-based fair value for Meihua International Medical Technologies Co. Ltd. is $4.73 (as of Oct 3, 2026), built from audited fundamentals. The current price: $6.50.
What is the quality score of MHUAF?
Meihua International Medical Technologies Co. Ltd. has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Meihua International Medical Technologies Co. Ltd. (MHUAF)?
Our model-based price target is the fair value of $4.73 (as of Oct 3, 2026) from 21 valuation models. Cautious scenario $3.95, optimistic scenario $6.26. It is a calculation from audited fundamentals, not an analyst target.
What is the Meihua International Medical Technologies Co. Ltd. stock forecast for 2026?
Our models put fair value at $4.73, about −27% upside versus a price of $6.50 (overvalued). Cautious scenario $3.95, optimistic scenario $6.26. The calculation is refreshed regularly with new filings.
What is the revenue of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
Meihua International Medical Technologies Co. Ltd. reported trailing-twelve-month revenue of about $61.8M (latest available figure, as of Oct 3, 2026).
What growth is priced into Meihua International Medical Technologies Co. Ltd. (MHUAF)?
For today's price to be fair in a discounted-cash-flow model, Meihua International Medical Technologies Co. Ltd. would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -7.1 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of MHUAF use?
Our models discount Meihua International Medical Technologies Co. Ltd. at 9.6 %: a base by market capitalisation (nano), damped by beta 0.95, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Meihua International Medical Technologies Co. Ltd. that is less than minus 40 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has Meihua International Medical Technologies Co. Ltd. (MHUAF) delivered so far?
Over the past 5 years revenue at Meihua International Medical Technologies Co. Ltd. grew -7.1 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Meihua International Medical Technologies Co. Ltd. (MHUAF) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Meihua International Medical Technologies Co. Ltd. (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
The free-cash-flow yield on the price is 12.26 %: that much free cash flow Meihua International Medical Technologies Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Meihua International Medical Technologies Co. Ltd. it is $4.73 per share (as of Oct 3, 2026), against a price of $6.50. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Meihua International Medical Technologies Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, MHUAF trades above its calculated fair value: price $6.50, fair value $4.73, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MHUAF?
No. The price is what the market pays today ($6.50); the fair value is what the company's own numbers justify ($4.73). For Meihua International Medical Technologies Co. Ltd. the two are $1.77 per share apart. That gap is exactly why we show both numbers side by side.
How much is Meihua International Medical Technologies Co. Ltd. worth?
The market values Meihua International Medical Technologies Co. Ltd. at about $6.0M (market capitalisation, as of Oct 3, 2026). Per share that is $6.50; our models calculate a fair value of $4.73 per share.
What do the bullish and bearish scenarios say about MHUAF?
Our models span a range for Meihua International Medical Technologies Co. Ltd.: cautious scenario $3.95, base $4.73, optimistic $6.26 per share (as of Oct 3, 2026, price $6.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MHUAF?
Meihua International Medical Technologies Co. Ltd. trades at a price-to-earnings ratio of 0.4 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.73 is built from several models across several years. Other multiples: P/S 0.1.
How solid is the balance sheet of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
Balance-sheet figures for Meihua International Medical Technologies Co. Ltd. (as of Oct 3, 2026): return on equity 3.9%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is MHUAF from its 52-week high?
Meihua International Medical Technologies Co. Ltd. trades at $6.50, about 83% below its 52-week high of $38.80 and 217% above the low of $2.05 (as of Oct 15, 2026). Distance from the high says nothing about value: that is what the fair value of $4.73 is for.
Which stocks are comparable to Meihua International Medical Technologies Co. Ltd.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Meihua International Medical Technologies Co. Ltd. stock attractive at the current price?
The data as of Oct 3, 2026: price $6.50, calculated fair value $4.73 (−27%), Quality Score 36/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MHUAF calculated?
We run Meihua International Medical Technologies Co. Ltd. through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8 % above its aggregate fair value. Meihua International Medical Technologies Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
The closing price on Oct 15, 2026 was $6.50. Our model-based fair value is $4.73, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Meihua International Medical Technologies Co. Ltd. right now?
The price sits above even our optimistic bull case ($6.26). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Meihua International Medical Technologies Co. Ltd.
How large is the market capitalisation of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
The market capitalisation of Meihua International Medical Technologies Co. Ltd. is $6.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
The price-to-sales ratio of Meihua International Medical Technologies Co. Ltd. is 0.04 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
Earnings per share at Meihua International Medical Technologies Co. Ltd. are $18.04 (price ÷ EPS = P/E 0.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
The net margin of Meihua International Medical Technologies Co. Ltd. is 11.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
The return on equity (ROE) of Meihua International Medical Technologies Co. Ltd. is 3.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
On an EBIT basis the return on assets of Meihua International Medical Technologies Co. Ltd. is 9.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
The operating margin of Meihua International Medical Technologies Co. Ltd. is 21.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Meihua International Medical Technologies Co. Ltd. (MHUAF)?
Revenue at Meihua International Medical Technologies Co. Ltd. is growing −53.8% versus a year earlier (3y avg −15.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Meihua International Medical Technologies Co. Ltd. (MHUAF)?
Earnings per share at Meihua International Medical Technologies Co. Ltd. are growing −56.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Meihua International Medical Technologies Co. Ltd. (MHUAF) hold?
Meihua International Medical Technologies Co. Ltd. holds more cash than debt, $6.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Meihua International Medical Technologies Co. Ltd. in the live analysis
One click puts Meihua International Medical Technologies Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Some data
Oct 3, 2026